Bristol Myers Squibb gets USFDA priority review for lung cancer treatment Repotrectinib Ruchika Sharma1 Jun 2023 2:00 PM ISTNon-small cell lung cancer is one of the most common types of lung cancer, representing up to 84% of diagnoses.
Bristol Myers Squibb receives EMA panel recommendation for approval of Opdivo with chemotherapy for lung cancer patients Ruchika Sharma29 May 2023 11:30 AM ISTOpdivo is a programmed death-1 immune checkpoint inhibitor that is designed to uniquely harness the body's own immune system to help restore...
Janssen Milvexian gets USFDA fast track designation for Ischemic Stroke, Acute Coronary Syndrome, Atrial Fibrillation Ruchika Sharma26 May 2023 3:15 PM ISTRaritan: The Janssen Pharmaceutical Companies of Johnson & Johnson has announced that all three prospective indications for milvexian, an ...
Amphista Therapeutics achieves first discovery milestone in collaboration with Bristol Myers Squibb Ruchika Sharma7 May 2023 10:00 AM ISTCambridge: Amphista Therapeutics has announced the delivery of the first discovery milestone under its collaboration and license agreement with...
Bristol Myers Squibb gets European Commission nod for CAR T Cell therapy Breyanzi for relapsed or refractory large B-cell lymphoma after one prior therapy Ruchika Sharma5 May 2023 2:30 PM ISTBreyanzi is a CD19-directed CAR T cell therapy with a 4-1BB costimulatory domain, which enhances the expansion and persistence of the CAR T cells.
Bristol Myers Squibb gets USFDA priority review for expanded Reblozyl use Ruchika Sharma1 May 2023 5:31 PM ISTReblozyl, a first-in-class therapeutic option, promotes late-stage red blood cell maturation in animal models.
Giovanni Caforio to retire as Bristol Myers Squibb CEO Ruchika Sharma30 April 2023 1:30 PM ISTNew York: Bristol Myers Squibb has announced that Giovanni Caforio, MD, Chairman of the Board and Chief Executive Officer, has decided to retire...
Bristol Myers Squibb gets positive CHMP opinion recommending nod for CAMZYOS for treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy Ruchika Sharma30 April 2023 12:15 PM ISTPrinceton: Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
Bristol Myers Squibb, Tubulis ink pact for development of next generation ADCs for cancer patients treatment Ruchika Sharma23 April 2023 11:00 AM ISTThe terms of the agreement include an upfront payment of USD 22.75 million to Tubulis in addition to the potential for over USD 1 billion in...
Bristol Myers Squibb gets positive EMA Committee opinion for Breyanzi for Relapsed or Refractory Large B-cell Lymphoma after one prior therapy Ruchika Sharma2 April 2023 10:00 AM ISTBreyanzi is a CD19-directed CAR T cell therapy with a 4-1BB costimulatory domain, which enhances the expansion and persistence of the CAR T cells.
Bristol Myers Squibb Sotyktu gets European Commission nod for adults with plaque psoriasis Ruchika Sharma30 March 2023 1:24 PM ISTSotyktu is an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor with a unique mechanism of action, representing a new class of small...
Bristol Myers Squibb Reblozyl gets European Commission nod for anemia due to Beta Thalassemia Ruchika Sharma5 March 2023 11:30 AM ISTReblozyl, a first-in-class therapeutic option, promotes late-stage red blood cell maturation in animal models.
